The challenge for long time followers is that we have been here many times debating what may happen in this or that situation. Try to remember the KISS principal firstly and add or subtract depending on what you believe may be relivant to you.

If you believe the sale price will be $2 billion (always in US$) and we will have 2X's more shares outstanding than we do today then you believe that your investment will be 4X's its current C$ price today. If the events that lead to a partnership or sale of the company warrant a valuation that is higher than $2 billion then you may expect more. If you don't believe this drug is worth at least $2 billion then strongly consider whether the risk is worth the reward for this investment. With all of the medical challenges that could benefit from ABL the potential market appears to be in excess of $10 billion and that may be low. There are any number of types of deals to be made so who cares if more shares are issued to get to a deal. There are enough benefits to a potential buyer today that would suggest a deal that would lean toward favor in RVX's advantage but if that is not the case there is still lots of money to be made for every party.

A clear path forward like todays news release is a hugh step in the direction of commercialization. The potential market is massive. The eventual winner of this prize is not only going to win because of this drugs ability but the ability of the whole epigenetic platform.

Todays news has set the stag for the next leg of this journey. The path to commercialization is almost in sight now.

Jump on, jump off or stay the course.

tada